Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

• Status: Unknown status
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Insulin; Insulin, Globin Zinc; Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• diabetes with gut dysbiosis

Exclusion Criteria:

• recent antibiotic use

• pregnancy

• diabetogenic drugs